NLRP3 and gastric cancer: Various studies have confirmed that the NLRP3-mediated release of IL-18 [41,42,43] or IL-1β [44,45,46,47] enhances the malignancy of lymphoma, gastric cancer, breast cancer, colon cancer, and glioblastoma via promoting the proliferation of cancer, immunosuppression, angiogenesis, and metastasis [48,49].